KYE Pharmaceuticals Inc. today announced it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of Accrufer® (ferric maltol). If approved, Accrufer® would be the first prescription only oral iron therapy approved by Health Canada and marketing approval for Accrufer® is expected to be during the first half…
eTurboNews nkhani ndi za olembetsa okha. Kulembetsa ndi FREE.
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
Olembetsa amalowa pano Dinani apa kuti mulembetse KWAULERE
ZOMWE MUNGACHITE PA NKHANIYI:
- lero yalengeza kuti yatumiza New Drug Submission (NDS) ku Health Canada kuti iwunikenso ndikuvomereza Accrufer® (ferric maltol).
- If approved, Accrufer® would be the first prescription only oral iron therapy approved by Health Canada and marketing approval for Accrufer® is expected to be during the first half….
- eTurboNews nkhani ndi za olembetsa okha.
